<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04253860</url>
  </required_header>
  <id_info>
    <org_study_id>TENS-ND-2018</org_study_id>
    <nct_id>NCT04253860</nct_id>
  </id_info>
  <brief_title>Effect of Transcutaneous Electrical Nerve Stimulation in Diabetic Neuropathy</brief_title>
  <official_title>Effect of Transcutaneous Electrical Nerve Stimulation on Pain percepción and Serum Inflammatory Markers in Patients With Peripheral Diabetic Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro Universitario de Tonalá</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Guadalajara</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Diabetes sin Complicaciones S.A de C.V, Mexico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centro Universitario de Tonalá</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double-blind, randomized, placebo-controlled, clinical trial. Patients with diabetic&#xD;
      neuropathy will be randomly assigned to treatment with either TENS or TENS sham three times a&#xD;
      week during 90 days. Clinical determinations are: pain, levesls of TNF-alpha, IL-6 and RPC-us&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to pandemic od COVID-19, was difficult recruit patients&#xD;
  </why_stopped>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Actual">July 30, 2021</completion_date>
  <primary_completion_date type="Actual">September 1, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blind, clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain perception</measure>
    <time_frame>Change from Baseline Pain perception at 90 days</time_frame>
    <description>Evaluation of neuropathic pain evaluated with VAS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumoral Necrosis Factor Alpha</measure>
    <time_frame>Change from Baseline serum levels of TNF-alpha at 90 days</time_frame>
    <description>Serum levels of TNF-alpha</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin-6</measure>
    <time_frame>Change from Baseline serum levels of IL-6 at 90 days</time_frame>
    <description>Serum levels of IL-6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C Reactive Protein ultra-sensible</measure>
    <time_frame>Change from Baseline serum levels of CRP-us at 90 days</time_frame>
    <description>Serum levels of CRP-us</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Diabetic Neuropathy Peripheral</condition>
  <arm_group>
    <arm_group_label>TENS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transcutaneous electrical neurostimulation will be applied for 30 minutes three times a week during 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>A sham comparator will be applied for 30 minutes three times a week during 90 days. The device does not emit electrical impulses</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcutaneous electrical neurostimulation</intervention_name>
    <description>Sessions of 30 minutes of TENS will be applied three times a week during 90 days</description>
    <arm_group_label>Sham</arm_group_label>
    <arm_group_label>TENS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnostic of type 2 diabetes &gt; 10 years&#xD;
&#xD;
          -  Diagnostic of peripheral diabetic neuropathy less than 5 years&#xD;
&#xD;
          -  HbA1C &gt; 6.5 and &lt; 9%&#xD;
&#xD;
          -  Plasmatic glucose &gt;140 mg/dL and lees than 350 mg/dL&#xD;
&#xD;
          -  Informed consent signed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of implanted pacemaker or heart defibrillator&#xD;
&#xD;
          -  Implanted brain stimulator&#xD;
&#xD;
          -  History of alcohol abuse&#xD;
&#xD;
          -  Use of NSAID, stereoids&#xD;
&#xD;
          -  Subjects with wounds, ulcers in legs&#xD;
&#xD;
          -  Subjects with hepatic, renal o neurologic diseases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arieh R Mercado Sesma, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Salud Enfermedad como proceso individual, CUTonalá, Universidad de Guadalajara</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>45425</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 30, 2020</study_first_submitted>
  <study_first_submitted_qc>January 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>July 29, 2021</last_update_submitted>
  <last_update_submitted_qc>July 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centro Universitario de Tonalá</investigator_affiliation>
    <investigator_full_name>Arieh Roldán Mercado Sesma</investigator_full_name>
    <investigator_title>Investigator</investigator_title>
  </responsible_party>
  <keyword>Diabetic neuropathy peripheral</keyword>
  <keyword>diabetic complications</keyword>
  <keyword>TENS</keyword>
  <keyword>Neuropathic treatments</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

